ASTRAZENECA PHARMA Q4 EARNINGS
Street votes for companies with no debt overhang to outlast tough times
Shares of 47 of 60 debt-free companies in BSE 500 index have gained as much as 100% in '19.
AstraZeneca Pharma Q4 profit jumps threefold to Rs 10 crore
Total income stood at Rs 196.31 crore in the quarter, compared with Rs 153.06 cro...
Sun Pharma Q4 profit halves to Rs 636 crore as expenditure grows 15%
Revenue came in at Rs 7,163.92 crore against Rs 6,977.10 crore on a year...
Sun in transition, stock to stay in range
For now, long-term investors will have to wait and watch.
Stocks in the news: Grasim, JSW Steel, Ashok Leyland, Sun TV and Page Industries
Larsen and Toubro on Thursday acquired over 4.5 lakh shares of Mindtree from open market.
Current rally picked up pace as earnings season got on: Vivek Mavani
BEL and KEI are two of Vivek Mavani’s midcap favourites.
What to watch out for in Sun Pharma’s Q4 results
The drug major is expected to post a 12.3 per cent increase in net sales to Rs 7,537 crore.
The week that was in 10 stocks: These scrips rallied up to 78%, telcos rang louder
Here are the top stocks and sectors that created all the buzz during the week gone by.
Cipla Q4 profit beats estimates; top highlights
In Q4, North America delivered strong growth of 41 per cent YoY and 38 per cent QoQ.
Dr Reddy's Q4 profit jumps 44% YoY to Rs 434 crore; Ebitda margin improves to 22%
Sales for the quarter rose 14 per cent to Rs 4,016.60 crore from Rs 3,534.90 crore.
Stocks in the news: TCS, Infosys, Jet Airways, GVK Infra and IDBI Bank
Department of Telecom has given approval for the merger of Tata Teleservices (TTSL) with Bharti Airtel.
Look which stocks found favour with the largest domestic investor in Q4
The banking sector emerged a tempting bet during the quarter.
F&O expiry, FII flow, macro data among 8 factors that will steer market next week
The coming week may see more volatility due to the expiry of May series F&O contracts.
125 firms posted two-fold jump in Q4 profit; are they worth a look?
Hemang Jani, Senior VP, Sharekhan said that only a few sectors are showing signs of revival.
AstraZeneca Pharma India Q4 net loss at Rs 2.87 crore
The company's total income from operations stood at Rs 111.57 crore for the quarter under consideration. It was Rs 158.82 crore for the same period a year ago.
Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service